Tag Archives: Biotech

FDA names 9 first recipients of 1- to 2-month priority review vouchers – Fierce Biotech

FDA names 9 first recipients of 1- to 2-month priority review vouchers  Fierce Biotech FDA unveils drugs to receive expedited review in support of ‘national priorities’  AP News FDA announces first nine recipients of priority drug review vouchers | STAT  statnews.com FDA unveils nine drugs getting streamlined reviews  Axios US FDA announces recipients of national priority vouchers  Reuters Source link

Read More »

Biotech Startup Claims It’s Getting Closer to ‘Resurrecting’ the Extinct Dodo

Biotech Startup Claims It’s Getting Closer to ‘Resurrecting’ the Extinct Dodo

A version of the dodo bird (Raphus cucullatus) could make a return someday soon. Colossal Biosciences announced this week several milestones in its quest to bring the extinct species back to life. On Wednesday, the Dallas-based company reported that its researchers at the Avian Genetics Group have successfully grown pigeon primordial germ cells (PGCs) in the lab, a scientific first. …

Read More »

Novartis assembles 2nd molecular glue deal with Monte Rosa, this one worth up to $5.7B – Fierce Biotech

Novartis assembles 2nd molecular glue deal with Monte Rosa, this one worth up to $5.7B  Fierce Biotech Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases  GlobeNewswire Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics  Yahoo Finance Updated: Novartis extends deal spree with $120M for Monte Rosa’s immune degraders  Endpoints News Novartis dives deeper into protein …

Read More »

Eli Lilly reconsiders UK biotech incubator, pauses buildout – Fierce Biotech

Eli Lilly reconsiders UK biotech incubator, pauses buildout  Fierce Biotech US urged UK to offer better drug pricing deal to pharma companies  Financial Times Lilly’s UK Gateway Labs plans are up in the air in latest blow to region’s biopharma industry  Endpoints News Eli Lilly joins big pharma fallout over drug prices  The Observer Ministers scramble to gag drug giants amid fears of Trump …

Read More »

Trump admin mulls 'severe restrictions' on US pharmas licensing Chinese meds: NYT – Fierce Biotech

Trump admin mulls ‘severe restrictions’ on US pharmas licensing Chinese meds: NYT  Fierce Biotech U.S. Drugmakers Warn White House of Chaos as Trump Weighs Curbs on China  The New York Times China Drugmaker Stocks Drop on Report of Potential Trump Curbs  Bloomberg.com Rumored Trump Move Rattles China-Based Biotech Stocks  Investor’s Business Daily Hong Kong stocks slip from 4-year high amid fears of US sanctions …

Read More »

FDA moves to publish drug rejection letters in real time, releases new batch including Replimune's high-profile snub – Fierce Biotech

FDA moves to publish drug rejection letters in real time, releases new batch including Replimune’s high-profile snub  Fierce Biotech FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future ‘Real-Time’ Access  BioSpace In a first, FDA publishes complete response letters for ongoing drug applications  Endpoints News MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy  Yahoo Finance In major …

Read More »

NCI axes funding for pediatric brain cancer trial consortium, shifts focus to broader oncology group – Fierce Biotech

NCI axes funding for pediatric brain cancer trial consortium, shifts focus to broader oncology group  Fierce Biotech A major childhood brain cancer network is ending  statnews.com Pratiti Bandopadhayay: Urgent Need to Sustain Funding for Pediatric Brain Tumor Trials  Oncodaily HHS winds down pediatric brain tumor pact after 26 years, prioritizing other childhood cancer work  Endpoints News Parvati Tiwari: Advocates Express Alarm Over NCI’s Decision …

Read More »

Biotech Startup Tahoe Therapeutics Raised $30 Million To Build AI Models Of Living Cells

Biotech Startup Tahoe Therapeutics Raised  Million To Build AI Models Of Living Cells

Tahoe cofounders (L-R): Kevin Shokat, Nima Alidoust, Johnny Yu and Hani Goodarzi Tahoe Therapeutics One of the holy grails of biology is digitally simulating a living cell. If researchers can use computers to more accurately understand how new medicines would react in the body, that could give them greater confidence when they’re tested on animals and humans. But while large …

Read More »

IO Biotech Melanoma Drug Shows 19.4-Month PFS in Phase 3 Trial Despite Statistical Miss

IO Biotech Melanoma Drug Shows 19.4-Month PFS in Phase 3 Trial Despite Statistical Miss

IO Biotech (NASDAQ: IOBT) announced topline results from its pivotal Phase 3 trial of Cylembio® plus KEYTRUDA® for first-line advanced melanoma treatment. While the combination showed clinical improvement in progression-free survival (19.4 months vs. 11.0 months), it narrowly missed statistical significance with HR=0.77 (p=0.056). Notable findings include a profound effect in PD-L1 …

Read More »